drugset

drugset / Trial / NCT00631462

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

NCT00631462 ↗

Phase 1 Completed 59 enrolled TargeGen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Timeline

Start: 2008-01
Primary completion: 2009-10
Completion: 2009-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fedratinib	Small molecule	—	Oral

Indications